Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

NICE Recommends Against Fludarabine For First-Line Treatment Of CLL

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Final Appraisal Determination concludes that Fludara monotherapy is not cost effective compared to chlorambucil.

You may also be interested in...



Xanthus Will Develop Oral Fludarabine For U.S. Market

Schering AG opts to out-license the oncologic rather than invest in further clinical study to support U.S. approval of the new dosage form.

Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward

Bayer will buy Merck’s shares in Schering AG at €89 per share, or €3 more than the current bid.

Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007

Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By